Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial immune profiling complements genomic sequencing in biliary tract cancer: hypothesis-generating use cases.

ESMO gastrointestinal oncology·2026
Same author

Frequent high-level rifaximin resistance in <i>Escherichia coli</i> associated with long-term treatment of patients with liver cirrhosis: a prospective, controlled study.

Microbiology spectrum·2025
Same author

The German Network for Personalized Medicine to enhance patient care and translational research.

Nature medicine·2023
Same author

[Correction: Colorectal carcinoma].

Deutsche medizinische Wochenschrift (1946)·2022
Same author

High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature.

Nature communications·2022
Same author

[Colorectal carcinoma].

Deutsche medizinische Wochenschrift (1946)·2021

Related Experiment Video

Updated: Jul 19, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

[Therapy of hepatitis B].

R Thimme1, H E Blum

  • 1Abteilung Innere Medizin II, Medizinische Universitätsklinik Freiburg. thimme@med1.ukl.uni-freiburg.de

Praxis
|September 23, 2006
PubMed
Summary

Hepatitis B virus (HBV) affects 350 million globally. Current treatments like interferon alpha, lamivudine, and adefovir show variable efficacy, necessitating personalized strategies to prevent severe liver disease.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis B virus (HBV) infection impacts 350 million individuals worldwide.
  • Liver disease, including cirrhosis, hepatic failure, and hepatocellular carcinoma, results in 0.5 to 1 million deaths annually.
  • Effective management of chronic HBV is crucial for preventing disease progression and mortality.

Purpose of the Study:

  • To review current therapeutic options for hepatitis B.
  • To discuss the factors influencing antiviral efficacy.
  • To emphasize the need for individualized treatment strategies in HBV management.

Main Methods:

  • Review of currently approved therapeutic options for hepatitis B.
  • Analysis of virological and clinical parameters affecting treatment outcomes.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Last Updated: Jul 19, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

  • Discussion of individualized treatment approaches.

    • Main Results:

    • Approved treatments include interferon alpha, lamivudine, and adefovir.
    • Treatment efficacy is significantly influenced by patient-specific virological and clinical factors.
    • No single treatment strategy is universally optimal.

    Conclusions:

    • Substantial advancements in hepatitis B treatment have been achieved.
    • Personalized treatment strategies are essential for optimizing outcomes in hepatitis B patients.
    • Further research into tailoring therapies based on individual parameters is warranted.